

REMARKS**I. Summary of Examiner Interview**

The undersigned would like to thank Examiner Yuan and Examiner Fiorilla for the helpful interview of December 8, 2010 in which various amendments of the claims were discussed. In particular, Applicants offered to amend claim 127 as proposed above to remove the “moiety” term and resolve any issues relating to clarity of the claims. As discussed in the interview, Applicants believe claim 127 as amended is fully supported by the specification particularly at page 15, lines 12-34, which provides support for not only derivatized compounds comprising C₆₀ or C₇₀ but also a wide variety of other products incorporating these molecules. Accordingly, claim 127 as amended clearly satisfies the written description requirement of 112, first paragraph. As further discussed in the interview, in order to expedite prosecution, Applicants are prepared to cancel claims 128, 129, and 132 if amended claim 127 is allowed. In the alternative, if the Examiner is unable or unwilling to allow amended claim 127, Applicants have retained said claims, and respectfully request that the amendments to claims 127-129, 132-133, 150-151, and 153 be entered by the Examiner to put the claims in better form for appeal.

II. Amendments

Applicants respectfully submit that the amendments to the pending claims are appropriate under 37 CFR 1.116(b), as they comply with the requirements of form expressly set forth in the June 23, 2010 Office Action and/or present the rejected claims in better form for consideration on appeal. No prohibited matter has been added. Accordingly, Applicants request that the amendments be entered by the Examiner.

Claims 122-124, 126-151 and 153-163 are pending. Claims 122-124, 126, 130, and 131 have been allowed. Applicants have amended claims 127-129, 132-133, 150-151, and 153.

Claims 128, 129, and 132 were amended to incorporate the term “purified.” Support for this amendment can be found throughout the specification, including, for example, page 5, line 20 to page 6, line 22.

Claims 133 and 150 were amended to incorporate the preamble language of claim 122. Support for this amendment can be found throughout the specification, including, for example, page 11, lines 4-21. This amendment is consistent with the Examiner’s proposed amendments as

set forth in the final office action.

Claims 133, 150, and 153 have been amended to specify which cage molecules are referenced.

Claim 153 has been amended to depend from claim 150.

Claims 125 and 152 have been canceled.

Claim 127 has been amended and claims “[a] product comprising purified C₆₀ and/or C₇₀.[”] Support for this amendment can be found at page 2, lines 31-33, and page 15, lines 12-34. The specification describes numerous examples of products that incorporate the purified cage molecules of the invention. For example, page 15 states:

[t]he present new products C₆₀, C₇₀, or mixtures thereof have the similar utilities as graphite. However, they are particularly valuable for forming products of a higher order of stability than those formed from graphitic carbon, and can be processed into formed or molded products such as C₆₀ fibers, C₇₀ fibers, or mixtures thereof using standard processing techniques. In this regard, free-flowing, particulate C₆₀ and C₇₀ are of special value particularly for use in producing molded products, especially those extended in at least one direction. C₆₀, and C₇₀ are also useful for producing a low temperature C₆₀ vapor (300°-400°C.) and C₇₀ vapor of the respective molecules to produce low temperature atomic and molecular beams of carbon which is not now possible using graphite as the carbon source. Further, the synthesis of compounds such as C₆₀H₆₀ and C₆₀F₆₀ can be accomplished by introducing hydrogen and fluorine, respectively, into a reactor containing C₆₀ vapor. Furthermore, the C₆₀ product and the C₇₀ product may be used as an industrial paint pigment or as a lubricant. Moreover, since the C₆₀ and C₇₀ molecule[s] are hollow, they could be used for binding and/or storing molecules, e.g., toxic material.

(‘890 Specification, Page 15, lines 12-34.)

Applicants believe that the innovative nature of this invention and the large number of disclosed products in the disclosure referenced above fully support and enable amended claim 127, and therefore, respectfully request entry of the claim amendment and allowance of the claim.

Except for issue fees payable under 37 C.F.R. 1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. §§ 1.16 and 1.17 which my be required, including

any required extension of time fees, or to credit any overpayment to Deposit Account 50-1283.

This paragraph is intended to be a **Constructive Petition for Extension of Time** in accordance with 37 C.F.R. 1.136(a)(3).

Dated: December 23, 2010

COOLEY LLP
CUSTOMER NUMBER 58249
ATTN: Patent Group
777 6th Street, NW, Suite 1100
Washington, DC 20001
Tel: (202) 842-7865
Fax: (202) 842-7899

By:

Respectfully submitted,
COOLEY LLP



Bonnie Weiss McLeod
Reg. No. 43,255